

Study Title: Long term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis (RMS) newly started on oral cladribine - CLARION

Study Protocol Date / Version: 19 June 2018/ Version 1.9

COMPOSITION OF STUDY STEERING COMMITTEE

External Members:

Role	Member	Country	Main expertise
Chairperson/ Moderator	Helmut Butzkueven	Australia	Neurology
Members	Joseph Berger	USA	Neurology/Infectious disease
	Maria Trojano	Italy	Neurology
	Nicholas Moore	France	Pharmacoepidemiology
	Tjalf Ziemssen	Germany	Clinical Neuroscience
	Philip Schein	USA	Oncology
	Sandra Vukusic	France	Neurology
	Christoph Thalheim	Belgium	Patients' representative
	Tomas Olsson	Sweden	Neurology
	Melinda Magyari	Denmark	Neurology

Merck Members:

Role	Name
Associate Director, Global Epidemiology	Meritxell Sabidó
Senior Clinical Research Manager, Regional Clinical Operations	Cristina Pinuaga Astorga
Director, Global Biostatistics	Doris Damian
Medical Director, Global Patient Safety	Axel Nolting